Interrelation of irritable bowel syndrome and bacterial overgrowth: is there any?
Abstract
The aim of review. To estimate possible interrelation between bacterial overgrowth syndromes in the small intestine (BOS) and irritable bowel syndrome (IBS).
Key points. BOS and IBS are extremely common syndromes, that contributes to their casual coexistence within same patient from epidemiological point of view. Clinical symptoms of BOS and IBS include meteorism, abdominal pain and disorders of defecation, that are difficult, at first sight, for differential diagnostics. From positions of pathophysiology it is possible to believe, that the IBS causes background for development of BOS, on the contrary, BOS increases risk of IBS development. Unfortunately, despite of huge quantity of studies, there is lack of convincing evidence to this for the present time. The evidential base is generated according to the studies showing high frequency of pathological breath tests in patients with IBS in comparison to healthy patients, however at IBS the rapid intestinal transit can promote false-positive results of breath tests. Other portion of evidential data is based on empirical application of nonabsorbable antibiotics that results in reduc tion of IBS symptoms. Failure to cure IBS by enteroantiseptic drugs requires necessity of search for new ways of treatment, including agents with enterosorptive action, capable to reduce BOS, velocity of intestinal transit and manifestations of IBS.
About the Authors
Yu. A. Kucheryavy
State educational government-financed institution of higher professional education «Yevdokimov Moscow State University of Medicine and Dentistry» Ministry of Healthcare of the Russian Federation
Russian Federation
Russian Federation
S. V. Cheryomushkin
State educational government-financed institution of higher professional education «Yevdokimov Moscow State University of Medicine and Dentistry» Ministry of Healthcare of the Russian Federation
Russian Federation
Russian Federation
Ye. A. Mayevskaya
State educational government-financed institution of higher professional education «Yevdokimov Moscow State University of Medicine and Dentistry» Ministry of Healthcare of the Russian Federation
Russian Federation
Russian Federation
Ye. A. Sutugina
State educational government-financed institution of higher professional education «Yevdokimov Moscow State University of Medicine and Dentistry» Ministry of Healthcare of the Russian Federation
Russian Federation
Russian Federation
References
1. Бондаренко В.М., Мацулевич Т.В. Дисбактериоз кишечника как клинико-лабораторный синдром: современное состояние проблемы: Руководство для врачей. – М.: ГЭОТАР-Медиа, 2007. – 304 с.
2. Денисов Н.Л., Светов К.В. Синдром избыточного бактериального роста у больных с синдромом раздраженного кишечника и язвенным колитом // Клин. перспективы гастроэнтерол. гепатол. – 2011. – № 3. – С.22–26.
3. Кучерявый Ю.А., Оганесян Т.С. Синдром избыточного бактериального роста // Рос. журн. гастроэнтерол. гепатол. колопроктол. – 2010. – Т. 20, № 5. – С. 63–68.
4. Маев И.В., Ивашкина Н.Ю., Кучерявый Ю.А., Оганесян Т.С. Диагностика и лечение синдрома избы точного бактериального роста в тонкой кишке // Экспер. клин. гастроэнтерол. – 2011. – № 3. – С. 125–129.
5. Маев И.В., Кучерявый Ю.А., Ивашкина Н.Ю., Данилевская Н.Н. Эффективность смекты при острой диарее у взрослых // Врач. – 2012. – № 1. – С. 42–45.
6. Маев И.В., Кучерявый Ю.А., Черёмушкин С.В. Эволюция представлений о синдроме раздраженного кишечника: Метод. рек. для врачей. – М., 2013. – 80 с.
7. Маевская Е.А., Черёмушкин С.В., Кривобородова Н.А., Кучерявый Ю.А. Синдром избыточного бактериального роста в тонкой кишке: от последних научных данных к рутинной практике // Клин. перспективы гастроэнтерол. гепатол. – 2013. – № 5. – С. 30–41.
8. Полуэктова Е.А., Кучумова С.Ю., Шептулин А.А., Ивашкин В.Т. Лечение синдрома раздраженного кишеч ника с позиций современных представлений о патогенезе заболевания // Рос. журн. гастроэнтерол. гепатол. колопроктол. – 2013. – Т. 23, № 1. – С. 57–65.
9. Черёмушкин С.В. Эффективность использования пробиотиков при синдроме раздраженного кишечника: Автореф. дис. … канд. мед. наук. – М., 2000. – 20 с.
10. Abrams G.D., Bishop J.E. Effect of the normal microbial flora on gastrointestinal motility // Proc. Soc. Exp. Biol. Med. – 1967. – Vol. 126 (1). – P. 301–304.
11. Barbara G., Stanghellini V., de Giorgio R. et al. Activated mast cells in proximity to colonic nerves correlate with abdominal pain in irritable bowel syndrome // Gastroenterology. – 2004. – Vol. 126 (3). – P. 693–702.
12. Barbara G., Wang B., Stanghellini V. et al. Mast cell-dependent excitation of visceral-nociceptive sensory neurons in irritable bowel syndrome // Gastroenterology. – 2007. – Vol. 132 (1). – P. 26–37.
13. Bures J., Cyrany J., Kohoutova D. et al. Small intestinal bacterial overgrowth syndrome // World J. Gastroenterol. – 2010. – Vol. 28. – P. 2978–2990.
14. Caenepeel P., Janssens J., Vantrappen G. et al. Interdigestive myoelectric complex in germ-free rats // Dig. Dis. Sci. – 1989. – Vol. 34 (8). – P. 1180–1184.
15. Chang F.Y., Lu C.L., Chen C.Y., Luo J.C. Efficacy of dioctahedral smectite in treating patients of diarrheapredominant irritable bowel syndrome // J. Gastroenterol. Hepatol. – 2007. – Vol. 22. – P. 2266–2272.
16. Choung R.S., Ruff K.C., Malhotra A. et al. Clinical predictors of small intestinal bacterial overgrowth by duodenal aspirate culture // Aliment. Pharmacol. Ther. – 2011. – Vol. 33 (9). – P. 1059–1067.
17. Drossman D.A. The functional gastrointestinal disorders and the Rome III process // Gastroenterology. – 2006. – Vol. 130 (5). – P. 1377–1390.
18. Dunlop S.P., Jenkins D., Spiller R.C. Distinctive clinical, psychological, and histological features of postinfective irritable bowel syndrome // Am. J. Gastroenterol. – 2003. – Vol. 98 (7). – P. 1578–1583.
19. Ford A.C., Spiegel B.M., Talley N.J., Moayyedi P. Small intestinal bacterial overgrowth in irritable bowel syndrome: systematic review and meta-analysis // Clin. Gastroenterol. Hepatol. – 2009. – Vol. 7. – P. 1279–1286.
20. Gwee K.A., Leong Y.L., Graham C. et al. The role of psychological and biological factors in postinfective gut dysfunction // Gut. – 1999. – Vol. 44 (3). – P. 400–406.
21. Hooper L.V., Gordon J. Commensal host-bacterial relationships in the gut // Science. – 2001. – Vol. 292 (5519). – P. 1115–1118.
22. Husebye E., Hellstrom P.M., Midtvedt I. Intestinal microflora stimulates myoelectric activity of rat small intestine by promoting cyclic initiation and aboral propagation of migrating myoelectric complex // Dig. Dis. Sci. – 1994. – Vol. 39 (5). – P. 946–956.
23. Husebye E., Hellstrom P.M., Sundler F. et al. Influence of microbial species on small intestinal myoelectric activity and transit in germ-free rats // Am. J. Physiol. Gastrointest. Liver Physiol. – 2001. – Vol. 280 (3). – P. 368–380.
24. Iwai H., Ishihara Y., Yamanaka J. et al. Effects of bacterial flora on cecal size and transit rate of intestinal contents in mice // Jpn. J. Exp. Med. – 1973. – Vol. 43(4). – P. 297–305.
25. Justensen T., Haagen Nielsen O., Jacobson E. The normal cultivable microflora in upper jejunal fluid in healthy adults // Scand. J. Gastroneterol. – 1984. – Vol. 19. – P. 279–282.
26. Kassinen A., Krogius-Kurikka L., Makivuokko H. et al. The fecal microbiota of irritable bowel syndrome patients differs significantly from that of healthy subjects // Gastroenterology. – 2007. – Vol. 133 (1). – P. 24–33.
27. Kerckhoffs A.P., Samsom M., van der Res M.E. et al. Lower Bifidobactena counts in both duodenal mucosa-associated and fecal microbiota in irritable bowel syndrome patients // World J. Gastroenterol. – 2009. – Vol. 15 (23). – P. 2887–2892.
28. Lackner J.M., Gudleski G.D., Zack M.M. et al. Measuring health-related quality of life in patients with irritable bowel: can less be more? // Psychosom. Med. – 2006. – Vol. 68 (2). – P. 312–320.
29. Laird J.M., Olivar T., Lopez-Garcia J.A. et al. Responses of rat spinal neurons to distension of inflamed colon: role of tachykinin NK2 receptors // Neuropharmacology. – 2001. – Vol. 40 (5). – P. 696–701.
30. Lembo A., Zakko S.F., Ferreira N.L. et al. T1390 Rifaximin for the treatment of diarrhea-associated irritable bowel syndrome: short term treatment leading to long term sustained response // Gastroenterology. –2008. – Vol. 134 (4, suppl. 1). – P. 545.
31. Lovell R.M., Ford A.C. Effect of gender on prevalence of irritable bowel syndrome in the community: systematic review and meta-analysis // Am. J. Gastroenterol. –2012. – Vol. 107 (7). – P. 991–1000.
32. Malinen E., Renttila R., Kajander K. et al. Analysis of the rectal microbiota of irritable bowel syndrome patients and healthy controls with real-time PCR // Am. J. Gastroenterol. – 2005. – Vol. 100 (2). – P. 373–382.
33. Mann N.S., Limoges-Gonzales M. The prevalence of small intestinal bacterial overgrowth in irritable bowel syndrome // Hepatogastroenterology. – 2009. – Vol. 56. – P. 718–721.
34. Neal K.R., Hebden J., Spiller R. Prevalence of gastrointestinal symptoms six months after bacterial gastroenteritis and risk factors for development of the irritable bowel syndrome: postal survey of patients // BMJ. – 1997. – Vol. 314 (7083). – P. 779–782.
35. Neal K.R., Barker L., Spiller R.C. Prognosis in postinfective irritable bowel syndrome: a six year follow up study // Gut. – 2002. – Vol. 51 (3). – P. 410–413.
36. Pimentel M., Chow E.J., Lin H.C. Eradication of small intestinal bacterial overgrowth reduces symptoms of irritable bowel syndrome // Am. J. Gastroenterol. –2000. – Vol. 95 (12). – P. 3503–3506.
37. Pimentel M., Chow E.J., Lin H.C. Normalization of lactulose breath testing correlates with symptom improvement in irritable bowel syndrome. A doubleblind, randomized, placebo-controlled study // Am. J. Gastroenterol. – 2003. – Vol. 98 (2). – P. 412–419.
38. Pimental М., Chang C. Inflammation and Microflora // Gastroenterol. Clin. North. Am. – 2011. – Vol. 40 (1).– P. 69–85.
39. Pimentel M., Lembo A., Chey W.D. et al. Rifaximin therapy for patients with irritable bowel syndrome without constipation // N. Engl. J. Med. – 2011. – Vol. 364. – P. 22–32.
40. Posserud I., Stotzer P.O., Bjornsson E.S. et al. Small intestinal bacterial overgrowth in patients with irritable bowel syndrome // Gut. – 2007. – Vol. 56 (6). – P. 802–808.
41. Rezaie A., Nikfar S., Abdollahi M. The place of antibiotics in management of irritable bowel syndrome: a systematic review and meta-analysis // Arch. Med. Sci. – 2010. – Vol. 6 (1). – P. 49–55.
42. Rousseaux C., Thuru X., Gelot A. et al. Lactobacillus actdophilus modulates intestinal pain and induces opioid and cannabinoid receptors // Nat. Med. – 2007. – Vol. 13 (1). – P. 35–37.
43. Sanovic S., Lamb D.P., Blennerhassett M.G. Damage to the enteric nervous system in experimental colitis // Am. J. Pathol. – 1999. – Vol. 155 (4). – P. 1051–1057.
44. Scarpellini E., Giorgio V., Gabrielli M. et al. Prevalence of small intestinal bacterial overgrowth in children with irritable bowel syndrome: a case-control study // J. Pediatr. – 2009. – Vol. 155. – P. 416–420.
45. Shah E.D., Basseri R.J., Chong K., Pimentel M. Abnormal breath testing in IBS: a meta-analysis // Dig. Dis. Sci. – 2010. – Vol. 55 (9). – P. 2441–2449.
46. Sharara A., Aoun E., Abdul-Baki H. et al. A randomized double-blind placebo controlled trial of rifaximin in patients with abdominal bloating and flatulence // Am. J. Gastroenterol. 2006. – Vol. 101 (2). – P. 326–333.
47. Si J.M., Yu Y.C., Fan Y.J. et al. Intestinal microecology and quality of life in irritable bowel syndrome patients // World J. Gastroenterol. – 2004. – Vol. 10 (12). – P. 1802–1805.
48. Simon G.L., Gorbach S.L. The human intestinal microflora // Dig. Dis. Sci. – 1986. – Vol. 31. – P. 147–162.
49. Sperber A.D., Drossman D.A., Quigley E.M. The global perspective on irritable bowel syndrome: a Rome Foundation-World Gastroenterology Organisation symposium // Am. J. Gastroenterol. – 2012. – Vol. 107 (11). – P. 1602–1609.
50. Spiller R.C., Jenkins D., Thornley J.P. et al. Increased rectal mucosal enteroendocrine cells, T-lymphocytes, and increased gut permeability following acute Campylobacter enteritis and in post-dysenteric irritable bowel syndrome // Gut. – 2000. – Vol. 47 (6). – P. 804–811.
51. Tana C., Umesaki Y., Imaoka A. et al. Altered profiles of intestinal microbiota and organic acids may be the origin of symptoms in irritable bowel syndrome // Neurogastroenterol. Motil. – 2009. – Vol. 22 (5). – P. 512–519.
52. Törnblom H., Lindberg G., Nyberg B. et al. Fullthickness biopsy of the jejunum reveals inflammation and enteric neuropathy in irritable bowel syndrome // Gastroenterology. – 2002. – Vol. 123 (6). – P. 1972–1999.
53. Toskes P. Bacterial overgrowth of the gastrointestinal tract // Adv. Int. Med. – 1993. – Vol. 38. – P. 387–407.
54. Wang L.H., Fang X.C., Pan G.Z. Bacillary dysentery as a causative factor of irritable bowel syndrome and its pathogenesis // Gut. – 2004. – Vol. 53 (8). – P. 1096–1101.
55. Weston A.P., Biddle W.L., Bhatia P.S., Miner P.B.Jr. Terminal ileal mucosal mast cells in irritable bowel syndrome // Dig. Dis. Sci. – 1993. – Vol. 38 (9). – P. 1590–1595.
56. Whorwell P.J., Altringer L., Morel J. et al. Efficacy of an encapsulated probiotic Bifidobacterium infantis 35624 in women with irritable bowel syndrome // Am. J. Gastroenterol. – 2006. – Vol. 101 (7). – P. 1581–1590.
57. Yang X., Sheng L., Guan Y. et al. Synaptic plasticity: the new explanation of visceral hypersensitivity in rats with Trichinella spiralis infection? // Dig. Dis. Sci. –2009. – Vol. 54 (5). – P. 937–946.
58. Yu D., Cheeseman F., Vanner S. et al. Combined orocaecal scinthigraphy and lactulose hydrogen breath testing demonstrate that breath testing detects orocaecal transit, not small intestinal bacterial overgrowth in patients with IBS // Gut. – 2011. – Vol. 60 (3). – P. 334–340.
Review
For citations:
Kucheryavy Yu.A., Cheryomushkin S.V., Mayevskaya Ye.A., Sutugina Ye.A. Interrelation of irritable bowel syndrome and bacterial overgrowth: is there any? Russian Journal of Gastroenterology, Hepatology, Coloproctology. 2014;24(2):5-14. (In Russ.)
Views:
90
Email this article 
